Research programme: receptor-associated protein therapeutics - Horizon Therapeutics plc
Alternative Names: AmpTide; HepTide; NeuroTrans; RAP peptide; RAP-2s; RAP-NGF conjugates; Receptor-Associated Protein-Nerve Growth Factor conjugatesLatest Information Update: 06 Nov 2023
Price :
$50 *
At a glance
- Originator Raptor Pharmaceuticals Corp
- Developer Horizon Therapeutics plc; Raptor Pharmaceutical Corp
- Class
- Mechanism of Action Growth factor receptor modulators; Nerve growth factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C; Liver cancer; Mesothelioma; Neurodegenerative disorders
Most Recent Events
- 02 May 2019 Horizon Pharma is now called Horizon Therapeutics plc
- 04 Nov 2017 No recent reports of development identified for preclinical development in liver cancer in USA (Parenteral)
- 12 Aug 2014 HepTide™ is still in preclinical development for liver cancer in USA